They examined its efficacy for targeted delivery of Dtxl to prostate cancer cells and found that the conjugate is capable of specifically binding to tumor cells with PSMA over-expression, and then engulfed by the tumor cells to exert cellular toxicity and achieve targeted therapy. This evidence concerns the gene FOLH1 and prostate carcinoma.